Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Bone-seeking radiopharmaceutical
Strontium-89 chloride
Metastron · Sr-89
Bone-seeking beta-emitting radiopharmaceutical for painful bone metastases; partly renally excreted with caution in renal impairment, but myelosuppression — not nephrotoxicity — dominates.
Moderateestablished · approved 1993
Palliation of pain from multifocal osteoblastic (sclerotic) bone metastases, classically from prostate and breast cancer
Signature kidney injury
Electrolyte Wasting
Intrinsic nephrotoxicity is not a defining or well-quantified effect; the prominent toxicity is transient myelosuppression (e.g., reversible hematologic toxicity reported in roughly half of treated patients in small series). Renal events are uncommon and not reliably enumerated.
Source: Zorga & Birkenfeld, Ortop Traumatol Rehabil 2003 (myelosuppression-dominant)
Mechanism of kidney injury
Strontium-89 is not a classic tubular toxin; its dominant toxicity is hematologic (myelosuppression, especially thrombocytopenia) from marrow irradiation. The renal relevance is twofold and indirect: a substantial fraction of an injected dose is renally excreted (urinary elimination, greatest in the early days after administration), so impaired renal function reduces clearance and can increase retained radioactivity and marrow exposure — hence caution or relative contraindication in significant renal impairment. Any direct radiation effect on the kidney/urinary tract would be an exposure phenomenon (the 'atn'/radiation-exposure label is used cautiously here) rather than a frequent clinical event. Mild electrolyte effects are possible but not characteristic.
Clinical presentation
Predominantly a transient pain flare and myelosuppression (notably thrombocytopenia/leukopenia) over weeks. There is no characteristic renal syndrome; renal concern is theoretical/PK — reduced clearance in renal impairment increasing systemic and marrow radiation exposure. Mild electrolyte changes are uncommon.
Onset
Hematologic nadir typically develops over several weeks (e.g., weeks 4-8) given the long physical half-life; any renal/excretion-related concern relates to the early post-injection days when urinary excretion is highest.
Reversibility
Reversible
Anticancer mechanism
A calcium-analog beta-emitting radionuclide (physical half-life ~50.5 days) that, after intravenous injection, is preferentially taken up into the mineral matrix of osteoblastic bone metastases, delivering localized internal radiotherapy that palliates metastatic bone pain; it is not curative and is used for symptom control rather than tumor eradication.
Management
Management is largely hematologic — monitor and support blood counts, with transfusion or treatment delay as needed for cytopenias. There is no specific renal antidote; in renal impairment, weigh the increased retained-dose risk against palliative benefit and consider avoiding the agent. Supportive care for any electrolyte changes.
Risk factors
- Renal impairment (reduced excretion, increased retained dose/marrow exposure)
- Pre-existing marrow compromise or low platelet/WBC counts
- Urinary incontinence (radiation-safety/handling consideration)
- Extensive marrow involvement by tumor
Prevention
- Assess renal function before administration; use caution or avoid in significant renal impairment
- Verify adequate baseline blood counts and monitor afterward
- Encourage hydration and normal voiding to facilitate urinary clearance in the early days; observe radiation-safety urinary precautions
- Patient selection limited to osteoblastic metastases with adequate marrow reserve
Note · Key teaching point: strontium-89 is renally excreted, so renal impairment is a caution/relative contraindication — but the clinically dominant toxicity is myelosuppression, not nephrotoxicity. Newer bone-targeted radiopharmaceuticals (e.g., radium-223) have largely superseded it in many settings.
Clinical depth
Renal dose adjustment
No standardized renal dose-reduction scheme; instead, renal impairment is a caution/relative contraindication because reduced clearance increases retained activity and marrow exposure. Dosing is activity-based (e.g., ~150 MBq) per protocol with attention to baseline counts and renal function.
Dialyzability & ESKD dosing
Not a standard management consideration; once incorporated into bone mineral, strontium-89 is not meaningfully removed by dialysis. Early circulating/urinary fraction is renally handled, but dialysis is not used as antidotal clearance.
Differential diagnosis
Cytopenias after strontium-89 reflect marrow irradiation (expected) rather than renal disease; if azotemia appears, evaluate for dehydration, obstruction from prostate cancer, or other nephrotoxins rather than a primary strontium tubular lesion.
Monitoring
- Complete blood count, particularly platelets and white cells, at baseline and serially for weeks after dosing
- Renal function before administration
- Pain response (efficacy)
- Radiation-safety urinary precautions in the days after injection
Key trials & series
- Zorga & Birkenfeld (Ortop Traumatol Rehabil 2003): palliative Sr-89 series demonstrating effective bone-pain palliation with predominantly mild, transient hematotoxicity
- Liepe et al. (Semin Nucl Med 2021): dosimetry/biodistribution review of bone-seeking beta emitters including strontium-89, detailing excretion and normal-tissue dose
Clinical pearls
- Myelosuppression (especially thrombocytopenia) is the dominant, dose-limiting toxicity — check counts before and after.
- About a third or more of the dose is renally excreted; renal impairment is a caution/relative contraindication due to increased retained activity.
- Long physical half-life (~50 days) means a delayed hematologic nadir.
- Largely supplanted by radium-223 in modern bone-metastasis palliation in many centers.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Electrolyte WastingAcute Tubular Necrosis
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
PMIDStrontium-89 in palliative treatement of painfull bone metastases.Zorga P et al. · Ortop Traumatol Rehabil 2003 · PMID 18034034Clinical series of palliative Sr-89 showing efficacy for bone pain with predominantly mild, transient hematotoxicity — supports myelosuppression (not nephrotoxicity) as the dominant toxicity.PMIDDosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases.Liepe K et al. · Semin Nucl Med 2021 · PMID 34895886Dosimetry/biodistribution review covering strontium-89 excretion and normal-tissue (including marrow) radiation doses, underpinning the renal-excretion and marrow-toxicity considerations.LandmarkAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med 2017 · PMID 28467867Onconephrology context for interpreting indirect/exposure-related renal considerations versus intrinsic nephrotoxicity in cancer therapeutics.